| Document |
Document Title |
|
WO/2021/070941A1 |
The present invention provides a surfactant which has good lathering properties, good lather quality and solubility even in a weak acidic range where the pH is equivalent to that of the skin, while having a low viscosity that leads to hi...
|
|
WO/2021/065893A1 |
The purpose of the present invention is to provide a novel low-molecular-weight compound that exhibits agonistic activity on an orexin receptor and is expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the li...
|
|
WO/2021/063373A1 |
The present invention relates to a compound represented by formula I and a stereoisomer, tautomer, solvate, polymorph thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, a preparation meth...
|
|
WO/2021/059146A1 |
The present invention relates to a process for preparing 1,1,3 -trimethylindan-4-amine of formula (I), or a salt thereof, enriched in one of its two enantiomers, in particular the enantiomer (R), (I) which comprises the chiral separation...
|
|
WO/2021/062348A1 |
The present invention provides methods of reducing injury to rice and achieving weed control by treating the rice with both a safener and a microencapsulated Group 15 herbicide. Herein, the inventors demonstrate that the tolerance of fen...
|
|
WO/2021/022212A3 |
This disclosure provides SERPIN B1 polypeptides that possess neutrophil or pancreatic elastase inhibitory activity, and the elastase inhibition activity is resistant to oxidation by free radicals. The free radicals may a reactive oxygen ...
|
|
WO/2021/059287A1 |
A method of oxygenating a benzylic C-H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze...
|
|
WO/2021/046651A1 |
Provided herein are compounds of Formula A, methods for the preparation thereof, and uses thereof for treating or preventing bacterial infections.
|
|
WO/2021/050992A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2021/036256A1 |
The present application is suitable for use in the technical field of drug synthesis, and provides a method for synthesizing an HIV protease inhibitor intermediate compounds. The method comprises subjecting compound 1a to an asymmetric t...
|
|
WO/2021/033504A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution is introduced into a flow path (I); the triphosgene solution comes into contact with a solid catalyst, which is affixed to at least a...
|
|
WO/2021/033505A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution, a tertiary amine solution and an active hydrogen-containing compound solution are introduced into different flow paths and are cause...
|
|
WO/2021/034863A1 |
Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimiz...
|
|
WO/2021/032156A1 |
Disclosed are a method for synthesizing a carboxy-containing anthraquinone derivative, the obtained derivative, and a battery system comprising same. The method for synthesizing a carboxy-containing anthraquinone derivative comprises the...
|
|
WO/2021/031984A1 |
Disclosed are a carboxylic acid oxime ester compound and the use thereof as a herbicide and for preparing a microbicide. The carboxylic acid oxime ester compound is as represented by general formula I:
|
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2021/017645A1 |
The present invention relates to the field of medicine synthesis, relates to a racemic preparation method for preparing a chiral β-amino acid and a derivative thereof, and particularly relates to a racemization method for a sitagliptin ...
|
|
WO/2021/019555A1 |
A process for preparing 4-amino-2-hydroxy-4-oxobutanoic acid and intermediates thereof. The compound prepared by the present process is useful in management of diabetes. The present process yields 0.35gm, 63% of the desired compound. The...
|
|
WO/2021/005512A1 |
Compounds having general formula (I) with a high fungicidal activity are described, and their use for the control of phytopathogenic fungi of important agricultural crops.
|
|
WO/2021/001457A1 |
The present invention relates to crystalline salt forms of (R)-2-amino-3-phenylpropylcarbamate and a process for their preparation. The invention also relates to a pharmaceutical composition comprising one or more of the crystalline salt...
|
|
WO/2020/259471A1 |
Provided herein are oseltamivir analogs useful for the treatment and prevention of viral infections, pharmaceutical compositions comprising the same and methods preparation and use thereof.
|
|
WO/2020/262603A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, the drug containing, as an active ingredient, a compound having an antagonistic...
|
|
WO/2020/260514A1 |
Bis(2-haloacetamido)- compounds for use as linkers to chemically cross-linking multiple thiol groups, and particularly, although not exclusively, the thiol groups of cysteine amino acids in peptide chains are described, along with their ...
|
|
WO/2020/258709A1 |
The present invention relates to a synthesis method for ZP-1609, comprising the steps of: 1) selectively reacting to completion, 4-amino-L-proline tert-butyl ester with N-hydroxysuccinimide benzoate to obtain an intermediate product; 2) ...
|
|
WO/2020/262367A1 |
An unground Nε-long chain acylidine crystal production method that includes: preparing a solution having at least one type of Nε-long chain acylidine dissolved in an acidic or basic solvent including water and/or one type selected from...
|
|
WO/2020/260526A1 |
The present invention relates to a new class of tertiary amine derivatives of formula (I) and their uses for treating viral infections, particularly viral respiratory infections. The present invention further relates to pharmaceutical co...
|
|
WO/2020/261974A1 |
Provided is a novel optically active bisphosphine methane that is useful as a ligand for an asymmetric catalyst, has excellent oxidation resistance in the air, and is easy to handle. Also, provided is a transition metal complex using, as...
|
|
WO/2020/257716A1 |
Disclosed are cationic lipids which are compounds of Formula (A). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ...
|
|
WO/2020/249956A1 |
Compounds of general formula (I), which are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A. wherein A is defined as Formula.
|
|
WO/2020/248403A1 |
Disclosed is a novel method for preparing adiponitrile. According to the method, an adipic acid diester and ammonia gas are used as raw materials, and same are subjected to a catalytic ammonolysis-dehydration reaction to directly prepare...
|
|
WO/2020/252205A1 |
The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
|
|
WO/2020/252046A1 |
Provided herein are combinations of capsaicin and TrpV1 modulators that are useful for treating capsaicin-responsive diseases or disorders.
|
|
WO/2020/247567A1 |
The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.
|
|
WO/2020/247458A1 |
The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating va...
|
|
WO/2020/238885A1 |
The present application belongs to the technical field of drug application, relates to a treatment method of a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor, and specifically relates to the dosage of the drug.
|
|
WO/2020/238388A1 |
Disclosed are a calcium-based catalyst and a method for catalytically synthesizing an alkanolamide surfactant thereby, which belong to the technical field of surfactant synthesis. The present invention prepares a compounded calcium-based...
|
|
WO/2020/232530A1 |
There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.
|
|
WO/2020/229014A1 |
The invention concerns a compound of Formula (I) or a salt thereof, wherein R1 is H, (C1-C3)alkyl or CF3; R2 is H, (C1-C3)alkyl or CF3; A is CH2COOH, XCH2COOCH2CH3, XCH2COOH, XCH2CH2NH2, where X is nitrogen or oxygen atom; Ar is an aroma...
|
|
WO/2020/228436A1 |
The present invention relates to aromatic ring or heteroaromatic ring derivatives, a preparation method therefor and applications thereof in medicine. Specifically, the present invention relates to aromatic ring or heteroaromatic ring de...
|
|
WO/2020/226522A1 |
The present invention falls within the area of the synthesis of ionic liquids, namely it concerns a process of synthesis of the ionic liquid tetraoctylammonium di(2-ethylhexyl)-oxamate (IL-5) with a high degree of purity and its use in t...
|
|
WO/2020/221690A1 |
The invention relates to a method for producing urea, comprising: a) producing formamide on the basis of carbon dioxide, hydrogen and ammonia, wherein methyl formate or ammonium formate is formed as an intermediate product in a catalytic...
|
|
WO/2020/222171A1 |
Herein is described an ionic complex catalyst and a process for olefin oligomerization of C14–C24 normal alpha olefins utilizing the ionic complex catalyst.
|
|
WO/2020/212993A1 |
Described herein are methods of enhancing formation and/or growth of an adventitious root in a plant and/or plant tissue, and/or for promoting grafting unification, enhancing fruit size and/or reducing flowering in a plant. The method co...
|
|
WO/2020/210914A1 |
The invention relates to compounds for use in imaging and/or for the diagnosis of conditions or diseases associated with an altered level of Neprilysin (NEP/CD10) in a subject having, or suspected of having said conditions or diseases. I...
|
|
WO/2020/207129A1 |
Disclosed is an ammonium salt with a structural formula represented by formula (I). A synthesis method thereof comprises using 8 mol% zinc chloride as a catalyst, 5 mmol of 1-phenyl-1,3-butanedione, 1.2 g of benzylamine, and 40 mL of chl...
|
|
WO/2020/198939A1 |
The present invention provides a crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide. The crystalline form has good light stability, high temperature stability, and high humidity stability.
|
|
WO/2020/203248A1 |
Provided is a method for producing a 4-halogenobenzylamine derivative that includes bringing a 1-methylbenzylamine derivative represented by formula (1) into contact with a halogenating agent to effect halogenation in the presence of sul...
|
|
WO/2020/199757A1 |
The present invention relates to a sulfonylbenzamide derivative, a preparation method therefor, and a medical use thereof. Specifically, disclosed are a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvat...
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/203594A1 |
Provided is a fluorene derivative represented by formula (1). (In the formula, Z1 and Z2 are predetermined divalent groups, and Ar1 and Ar2 are each independently a C6-20 aryl group or a C2-20 heteroaryl group, and may be substituted wit...
|
